Trial Profile
The Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose Infusion.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Sponsors Eli Lilly and Company
- 02 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Jun 2011 Planned end date changed from Jul 2011 to Aug 2011 as reported by ClinicalTrials.gov.